Literature DB >> 30824356

Pneumocystis pneumonia in HIV-1-infected patients.

Satoshi Shibata1, Toshiaki Kikuchi2.   

Abstract

Pneumocystis pneumonia (PCP) is an opportunistic disease that mainly affects patients with a deficiency of cell-mediated immunity, especially acquired immunodeficiency syndrome (AIDS). The incidence of PCP in these patients has declined substantially owing to the widespread use of antiretroviral therapy and PCP prophylaxis. However, PCP is still a major AIDS-related opportunistic infection, particularly in patients with advanced immunosuppression in whom human immunodeficiency virus type 1 (HIV-1) infection remains undiagnosed or untreated. The clinical manifestations, diagnosis, treatment, and prevention of PCP in patients with HIV-1 infection are addressed in this review.
Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acquired immunodeficiency syndrome; Human immunodeficiency virus; Opportunistic infection; Pneumocystis pneumonia

Year:  2019        PMID: 30824356     DOI: 10.1016/j.resinv.2019.01.009

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  7 in total

1.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

2.  Efficacy and safety of ultrasound-guided intrathyroidal injection of glucocorticoids versus routine oral administration of glucocorticoids for subacute thyroiditis: Protocol of systematic review and meta-analysis.

Authors:  Jinyan Li; Ji Zhang; Li Jiang; Ziling Li; Fang Li; Huixia Chen; Ling Feng
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

3.  Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.

Authors:  Q Tian; J Si; F Jiang; R Xu; B Wei; B Huang; Q Li; Z Jiang; T Zhao
Journal:  HIV Med       Date:  2020-12-04       Impact factor: 3.180

4.  Cytopathological analysis of bronchoalveolar lavage fluid in patients with and without HIV infection.

Authors:  Xiang-Mei Chen; Lei Sun; Kun Yang; Jia-Min Chen; Liang Zhang; Xiao-Yi Han; Xingang Zhou; Zhi-Yuan Ma; Man Li; Hong-Xin Zhao; Li-Ming Qi; Peng Wang
Journal:  BMC Pulm Med       Date:  2022-02-08       Impact factor: 3.317

5.  Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.

Authors:  Yan-Ming Zeng; Yao Li; Yan-Qiu Lu; Min Liu; Jing-Min Nie; Jing Yuan; Vijay Harypursat; Yi-Hong Zhou; Yuan-Yuan Qin; Xiao-Hong Chen; Yu-Lin Zhang; De-Fa Zhang; Ni Wang; Hui Chen; Qun Tian; Yang Zhou; Ying-Mei Qin; Xin-Ping Yang; Yao-Kai Chen
Journal:  BMC Pulm Med       Date:  2022-08-25       Impact factor: 3.320

6.  Co-infection by Cryptococcus neoformans fungaemia and non-tuberculous mycobacteria with Pneumocystis jiroveci pneumonia in a newly diagnosed HIV-infected patient.

Authors:  Eihab A Subahi; Mohamad S Aljafar; Haidar H Barjas; Mohamed Abdelrazek; Fatima A Rasoul
Journal:  Clin Case Rep       Date:  2021-05-05

7.  Pneumocystis jirovecii pneumonia: a proposed novel model of corticosteroid benefit.

Authors:  Amal A Gharamti; William Mundo; Daniel B Chastain; Carlos Franco-Paredes; Andrés F Henao-Martínez; Leland Shapiro
Journal:  Ther Adv Infect Dis       Date:  2021-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.